Attrogy (diflunisal)
- Region
- 🇪🇺 EU
- Active substance
- diflunisal
- Company
- Purpose Pharma International AB
- Status
- Authorised
- Therapeutic area
- Amyloid Neuropathies, Familial
- CHMP opinion
- Fri 25 Apr 2025
- EU approval
- Thu 17 Jul 2025
- Application
- EMEA/H/C/006248
- ATC
- N02BA11
- Official record
- www.ema.europa.eu
Indication
Attrogy is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
Regulatory milestones
No milestones recorded in the last year.
Follow Attrogy
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.